Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CHRS Relative to the S&P 500

CHRS Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Coherus BioSciences Inc. (NASD:CHRS) seasonal charts above shows that a Buy Date of June 16 and a Sell Date of September 9 has resulted in a geometric average return of 14.98% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 44.15% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

To download CHRS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CHRS